Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
96% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. VSTM: No Debt )
VSTM' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Interest Coverage No Debt
VSTM's Interest Coverage is ranked higher than
82% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
VSTM' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 16.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -53.56
VSTM's ROE (%) is ranked higher than
64% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. VSTM: -53.56 )
VSTM' s 10-Year ROE (%) Range
Min: -82.33   Max: -39.63
Current: -53.56

-82.33
-39.63
ROA (%) -49.40
VSTM's ROA (%) is ranked higher than
62% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. VSTM: -49.40 )
VSTM' s 10-Year ROA (%) Range
Min: -47.67   Max: -37.77
Current: -49.4

-47.67
-37.77
ROC (Joel Greenblatt) (%) -2673.21
VSTM's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. VSTM: -2673.21 )
VSTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.21   Max: -3102.26
Current: -2673.21

-7948.21
-3102.26
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VSTM Guru Trades in Q2 2014

First Eagle Investment 512,254 sh (+0.20%)
Paul Tudor Jones Sold Out
» More
Q3 2014

VSTM Guru Trades in Q3 2014

Jim Simons 66,300 sh (New)
First Eagle Investment 512,254 sh (unchged)
» More
Q4 2014

VSTM Guru Trades in Q4 2014

Jim Simons 204,787 sh (+208.88%)
First Eagle Investment 302,622 sh (-40.92%)
» More
Q1 2015

VSTM Guru Trades in Q1 2015

Paul Tudor Jones 10,666 sh (New)
First Eagle Investment 427,622 sh (+41.31%)
Jim Simons 107,100 sh (-47.70%)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
VSTM's P/B is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. VSTM: 2.40 )
VSTM' s 10-Year P/B Range
Min: 0   Max: 4.9
Current: 2.4

0
4.9
EV-to-EBIT -2.99
VSTM's EV-to-EBIT is ranked higher than
66% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VSTM: -2.99 )
VSTM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.99

Current Ratio 14.26
VSTM's Current Ratio is ranked higher than
91% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. VSTM: 14.26 )
VSTM' s 10-Year Current Ratio Range
Min: 10.36   Max: 30.79
Current: 14.26

10.36
30.79
Quick Ratio 14.26
VSTM's Quick Ratio is ranked higher than
92% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. VSTM: 14.26 )
VSTM' s 10-Year Quick Ratio Range
Min: 10.36   Max: 30.79
Current: 14.26

10.36
30.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
VSTM's Price/Net Cash is ranked higher than
96% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. VSTM: 2.50 )
VSTM' s 10-Year Price/Net Cash Range
Min: 2.57   Max: 6.04
Current: 2.5

2.57
6.04
Price/Net Current Asset Value 2.50
VSTM's Price/Net Current Asset Value is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. VSTM: 2.50 )
VSTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.55   Max: 5.97
Current: 2.5

2.55
5.97
Price/Tangible Book 2.30
VSTM's Price/Tangible Book is ranked higher than
90% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. VSTM: 2.30 )
VSTM' s 10-Year Price/Tangible Book Range
Min: 1.98   Max: 3.87
Current: 2.3

1.98
3.87
Earnings Yield (Greenblatt) -32.50
VSTM's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. VSTM: -32.50 )
VSTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -60.4   Max: 0
Current: -32.5

-60.4
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany,
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including mesothelioma, ovarian and lung. The Company's solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company's competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting May 19 2015
Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting May 19 2015
The Road To The Cure: 4 Biotech Stocks Advancing New Therapies In The Fight Against Cancer May 17 2015
VERASTEM, INC. Financials May 16 2015
Verastem to Present at 2015 UBS Global Health Care Conference May 12 2015
Verastem to Present at 2015 UBS Global Health Care Conference May 12 2015
Verastem reports 1Q loss May 11 2015
Verastem reports 1Q loss May 11 2015
Verastem Reports First Quarter 2015 Financial and Corporate Results May 11 2015
VERASTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 11 2015
VERASTEM, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Verastem Reports First Quarter 2015 Financial and Corporate Results May 11 2015
Verastem to Present at Upcoming Investor Conferences Apr 30 2015
Verastem to Present at Upcoming Investor Conferences Apr 30 2015
Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at... Apr 22 2015
Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at... Apr 22 2015
Coverage initiated on Verastem by H.C. Wainwright Apr 08 2015
Gelesis Closes $22M Equity Financing Mar 26 2015
Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting Mar 19 2015
Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting Mar 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK